Immunocore Has Crossed the Line the Market Still Can't See

The market is still pricing Immunocore as a cash-burning biotech that happens to sell one approved drug. The Q2 earnings that dropped on August 6th say something different: this is a company that just posted its first profitable half-year ever, cut its quarterly operating loss by 80% year-over-year, and is sitting on $880 million in cash while the next major trial for its lead product nears completion.

The stock trades at $34. A recent competitor article flagged a "49% undervaluation" case, and while the exact provenance of that specific percentage is hard to pin down, the core question is worth answering on its own terms. Is the stock genuinely underpriced relative to where the operating setup is heading? The evidence points that way.

The inflection is already in the numbers

KIMMTRAK — Immunocore's bispecific T-cell engaging therapy for metastatic uveal melanoma — brought in $115.9 million in Q2, up 18% year-over-year. The full first half revenue of $223 million grew 16% versus the same period in 2025. More important than the top line is what happened underneath it.

The company reported net income of $12.2 million for H1, compared to a net loss of $5.3 million a year ago. The Q2 operating loss shrank to $3.0 million from $14.9 million. That is not a cosmetic accounting improvement. Revenue growth absorbed higher spending on three concurrent Phase 3 trials while moving the company to near-breakeven on an operating basis in a single quarter for the first time.

The five-year survival data presented at AACR in May anchors the commercial case: KIMMTRAK doubled the likelihood of being alive at five years versus control (16% versus 8%, hazard ratio 0.67). In a disease where median survival historically sat around 15 months, doubling the five-year rate is the kind of clinical signal that makes a drug the standard of care — which KIMMTRAK already is across 30+ launch countries.

What the market still can't let go of

The trailing-twelve-month free cash flow is negative $41 million. The operating margin stands at -8.3%. The stock is down 2% year-to-date and has been stuck below $40 since early 2025. Analyst consensus sits at "Hold" — five buys, five holds, one sell — with the aggregate price target trimmed to $33 by SimplyWallStreet after Jefferies downgraded from Buy to Hold in March.

That's the old story. And the market is anchored to it for two reasons.

First, the negative free cash flow TTM number looks ugly on any screen. But it's backward-looking, and the H1 2026 operating cash flow is already a fraction of what the annualized rate would suggest. Q2's near-breakeven operating result, combined with a 98.9% gross margin, means the cash-flow trajectory is bending sharply.

Second, the $120 million in sales-related rebate payments coming in H2 2026 will create a temporary cash-flow spike that could confuse quarterly cash-flow reporting. About half of that is from a French pricing agreement requiring catch-up payments for five prior years. Management expects rebates to normalize to $65–70 million in 2027. The $880 million cash balance absorbs this without strain.

The next 12 months

The question that separates a company that has temporarily stopped bleeding from one that's about to become something harder to dismiss comes down to the pipeline. Specifically, TEBE-AM.

This Phase 3 trial evaluates KIMMTRAK — both as monotherapy and combined with pembrolizumab — in previously treated advanced cutaneous melanoma. Enrollment of 540 patients is nearing completion. Topline data is expected as early as the end of 2026. Cutaneous melanoma is a substantially larger addressable market than uveal melanoma; management has flagged the potential to scale patient volume sixfold, from roughly 1,000 patients per year to up to 4,000.

If TEBE-AM delivers, the revenue base shifts from a $220M run-rate in a niche indication to a pipeline that could credibly approach $550 million in annual revenue within two years. That's the financial bridge.

The math

Current market cap: $1.75 billion. Enterprise value (market cap minus $486 million in net cash): $1.27 billion. On roughly $440 million of trailing revenue, the EV/sales multiple sits at 2.9x. That is cheaper than most commercial biotechs with a single approved product growing double digits — and this one has two additional Phase 3 programs (PRISM-MEL-301 in first-line cutaneous melanoma with brenetafusp, and ATOM in adjuvant uveal melanoma) still in the bag.

If TEBE-AM succeeds and Immunocore reaches $550 million in revenue by 2027 with a return to positive free cash flow, a 4x EV/sales multiple is not aggressive. It's in line with commercial biotechs that have demonstrated both revenue growth and a path to self-funding. That implies an enterprise value of roughly $2.2 billion. Adding back net cash of approximately $400 million (after H2 rebate payments and continued pipeline investment), the implied market cap is around $2.6 billion.

With roughly 51.5 million shares outstanding, that works out to about $50 per share. That's approximately 48% above the current price.

Target: $50 over 18 months. The condition is TEBE-AM data at or before the end of 2026, followed by regulatory discussion on a cutaneous melanoma expansion.

What could still break it

TEBE-AM is event-driven, meaning the timing is tied to outcomes, not calendar dates. A later-than-expected readout pushes the inflection point further out. A negative or inconclusive result would eliminate the sixfold volume expansion thesis and collapse the forward revenue assumption back toward the current ~$250 million annual run-rate. At that level, the stock would need to justify its valuation purely on modest uveal melanoma penetration gains, which is a far weaker story.

Beyond the binary trial risk, there's the softer question of growth trajectory. Management acknowledged "moderating growth" for KIMMTRAK in its fifth year, with penetration already above 70% in major markets. If the 18% revenue growth decelerates to single digits before TEBE-AM data arrives, the market's patience — already tested by a flat year-to-date price action — could thin further.

And yes, the H2 rebate payment will show up as a large cash outflow on the books. The Q3 or Q4 free cash flow could look brutal on a one-quarter basis. That's noise, not signal, but the tape doesn't always know the difference.

The setup

AInvest's aggregate signal still labels Immunocore a Buy, and the analyst crowd is split down the middle. The average target across coverage firms sits around $55 to $56, though that number is anchored by HC Wainwright's outlier call of $100 and Jefferies' floor of $33.

The point is not to argue with any single target. The point is that the stock is still priced as if the operating improvement hasn't happened yet. It has. The first profitable half-year, the near-breakeven quarter, the $880 million cash fortress, and the cutaneous melanoma trial all within six months — these are the facts that matter.

$50 over 18 months is not a guess. It's the result of assuming the trial works, revenue reaches a defensible $550 million, and the market assigns a multiple that commercial biotechs routinely trade at. Simple forward multiples beat complex models here because the binary event is the gating factor, not the discount rate.

The tripwire: TEBE-AM fails to meet its primary endpoint, or Immunocore reports two consecutive quarters of declining KIMMTRAK revenue. Either one breaks the bridge. Discipline over ego if either fires.

If the trial works and the stock dips on a bad cash-flow quarter from the rebate payment, that's the entry the market misread creates. The setup is clean.